Melanoma antigen preferentially expressed in tumors (425-433)

Melanoma antigen preferentially expressed in tumors (425-433) is a synthetic peptide fragment derived from the larger MAGE-A1 protein, a member of the melanoma antigen gene family. This nonapeptide corresponds to amino acid residues 425 through 433 of the MAGE-A1 sequence and is well-recognized for its immunogenic properties and its selective expression in various tumor tissues, especially melanoma. The peptide's unique sequence and tumor-associated origin make it a valuable tool for fundamental studies in tumor immunology, antigen processing, and peptide-based assay development. Its biochemical relevance extends to the exploration of antigen presentation pathways and the design of peptide-based platforms for research into tumor-specific immune responses.

Epitope mapping: Researchers utilize the 425-433 peptide fragment to delineate T-cell epitopes within the MAGE-A1 antigen. By exposing immune cells or antigen-presenting cells to this defined sequence, investigators can identify and characterize the specific regions recognized by cytotoxic T lymphocytes. This approach is essential for understanding the molecular basis of tumor antigen recognition and for mapping the minimal epitope required to elicit an immune response in the context of human leukocyte antigen (HLA) restriction.

Antigen processing studies: The synthetic peptide serves as a precise substrate for dissecting the pathways by which tumor-associated antigens are processed and presented by major histocompatibility complex (MHC) molecules. By introducing this defined fragment into in vitro systems, scientists can monitor peptide loading, stability, and presentation efficiency, thereby gaining mechanistic insights into antigen processing defects or enhancements in tumor cells. Such studies are critical for elucidating the steps leading to effective immune surveillance or immune evasion in cancer.

Peptide-MHC binding assays: The 425-433 sequence is widely employed in binding affinity assays to evaluate its interaction with specific HLA alleles, such as HLA-A1. These in vitro assays help quantify the peptide's binding strength, stability, and presentation dynamics, providing foundational data for the selection of optimal peptide candidates in immunological research. The results inform the rational design of experimental systems focused on antigen presentation and T-cell activation.

Development of immunoassays: The defined sequence of this peptide enables its use as a standard or probe in the development of sensitive immunoassays targeting MAGE-A1-specific immune responses. By incorporating this fragment into enzyme-linked immunosorbent assays (ELISAs), tetramer staining protocols, or other detection platforms, researchers can accurately monitor the presence and magnitude of antigen-specific T-cell populations. These immunoassays are indispensable for basic research into tumor immunology and for evaluating immune responsiveness in various experimental models.

Peptide-based screening platforms: The synthetic peptide is frequently integrated into high-throughput screening platforms aimed at identifying novel T-cell receptors or immune modulators with specificity for MAGE-A1-derived epitopes. By immobilizing or presenting the peptide in screening assays, investigators can systematically evaluate the reactivity of diverse immune repertoires, facilitating the discovery of unique T-cell clones or modulatory agents. This application supports the broader objective of advancing knowledge in tumor antigen recognition and immune modulation at the molecular level.

1. The effect of sex on immune responses to a homocitrullinated peptide in the DR4-transgenic mouse model of Rheumatoid Arthritis

2. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

3. Investigating Potential Interactions Between Neurohypophyseal Peptides, their Drug Analogs, and Coagulation Factor VIII

4. Quantitative Analysis of Ligands Effects on Bioefficacy of Nanoemulsion encapsulating Depigmenting Active

5. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists